Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

Abstract

Activating mutations in the neuroblastoma rat sarcoma viral oncogene homolog (NRAS) gene are common genetic events in malignant melanoma being found in 15-25% of cases. NRAS is thought to activate both mitogen activated protein kinase (MAPK) and PI3K signaling in melanoma cells. We studied the influence of different components on the MAP/extracellular signal-regulated (ERK) kinase (MEK) and PI3K/mammalian target of rapamycin (mTOR)-signaling cascade in NRAS mutant melanoma cells. In general, these cells were more sensitive to MEK inhibition compared with inhibition in the PI3K/ mTOR cascade. Combined targeting of MEK and PI3K was superior to MEK and mTOR 1,2 inhibition in all NRAS mutant melanoma cell lines tested, suggesting that PI3K signaling is more important for cell survival in NRAS mutant melanoma when MEK is inhibited. However, targeting of PI3K/mTOR 1,2 in combination with MEK inhibitors is necessary to effectively abolish growth of NRAS mutant melanoma cells in vitro and regress xenografted NRAS mutant melanoma. Furthermore, we showed that MEK and PI3K/mTOR 1,2 inhibition is synergistic. Expression analysis confirms that combined MEK and PI3K/mTOR 1,2 inhibition predominantly influences genes in the rat sarcoma (RAS) pathway and growth factor receptor pathways, which signal through MEK/ERK and PI3K/mTOR, respectively. Our results suggest that combined targeting of the MEK/ERK and PI3K/mTOR pathways has antitumor activity and might serve as a therapeutic option in the treatment of NRAS mutant melanoma, for which there are currently no effective therapies.O ncogenic mutations in codons 12, 13, or 61 of the rat sarcoma (RAS) family of small GTPases, Kirsten rat sarcoma viral oncogene homolog (KRAS), Harvey rat sarcoma viral oncogene homolog (HRAS), and neuroblastoma RAS viral oncogene homolog (NRAS) occur in approximately one-third of all human cancers with NRAS mutations found in about 15-20% of melanomas (1-7). Mutated RAS proteins activate signaling pathways that promote the cell division cycle and cell growth and suppress apoptosis. Small interfering RNA (siRNA)-mediated depletion of NRAS in melanoma cell lines inhibits proliferation and renders cells sensitive to chemotherapy, making mutant NRAS and its signaling effectors relevant targets for melanoma therapy (8, 9). Efforts at developing therapeutics that inhibit mutant RAS directly have so far not been successful. The high affinity of RAS for GTP and the high concentrations of GTP intracellularly has meant that the identification of small molecules, which selectively prevent accumulation of RAS-GTP, has not been possible (10). Targeting mutant NRAS with siRNA is still limited to preclinical models because of the significant challenge in delivering antisense oligonucleotides in vivo. The response of NRAS mutant melanoma and other melanomas to various chemotherapeutic regiments has been very scarce with only 6% of patients responding (11). Alternatively, farnesyltransferase inhibitors (FTIs) were thought to inhibit RAS activation by blocking farnesy...

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

“…Our finding that AKT inhibitors do not suppress ERK and are inferior to PI3K inhibitors in terms of induction of the proapoptotic molecule BIM and apoptosis suggests that PI3K inhibitors may have superior antitumor activity compared with AKT inhibitors for certain cancers. Previous studies have demonstrated that combined inhibition of both PI3K/AKT and ERK pathways are substantially more effective in promoting durable tumor regression in other cancer models (25)(26)(27)(28)(29)(30). However, the functional differences between PI3K and AKT inhibitors may extend beyond the regulation of P-Rex1 and ERK signaling.…”

A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma

“…[52] The mTOR pathway is involved in cell growth, proliferation, and survival, and in addition it affects downstream effector proteins which are essential for the protein translation processes. [52] It has been reported previously that the mTOR pathway is highly up regulated in malignant melanoma due to the NRAS mutation [53] and inhibiting the mTOR pathway can have beneficial effects in the treatment regimen. [54] EVR acts on the mTOR1 pathway and it is known that the cancer cells immediately up regulate the mTOR2 pathway to induce drug resistance when the mTOR1 pathway is blocked.…”

Empirical inference of circuitry and plasticity in a kinase signaling network

“…These two ubiquitous pathways form a network that regulates growth factor, antigen, and insulin signaling while also being deregulated in most cancers (15)(16)(17). We then measured the activity and plasticity of different routes within this experimentally defined kinase signaling network in cells chronically treated with small-molecule inhibitors of PI3K and mTORC1/2.…”